IMB-001 / Immunobiome - LARVOL DELTA

ImmunoBiome (BIO 2022) - "Based on our solid scientific infrastructures (Germ-Free mouse facility), qualified scientist (Immunologist and AI specialist), and merits of academic research environment (located in POSTECH campus), we could accelerate the development process and publish papers in prestigious academic journals. Currently, we are developing two LBP candidates, IMB001 and IMB002, targeting cancer and inflammatory disorders."

Immunology • Inflammation • Oncology

Immunobiome’s strategy to challenge ’microbiome anticancer drug’? [Google translation] (Biospectator) - "Immunobiome signed a contract for development and production of IMB-001...with Bios, a French microbiome consignment development and production (CDMO) company, in November, and the production of IMB-001 from the 1st. Started...'We plan to start phase 1 clinical trial of IMB-001 in the fourth quarter of next year'...'Based on this, we plan to promote an IPO in 2023.'"

Licensing / partnership • New P1 trial • Breast Cancer • Colon Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma